Buy Like Buffett
Watchlist

Flagship explainer

How Amphastar Pharmaceuticals, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$720M · 100%Cost of revenue$364M · 51%Gross profit$356M · 49%Operating income$140M · 20%Income before tax$124M · 17%Income tax$25.5M · 4%Net income$98.1M · 14%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$720M100%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
Cost of revenue$364M51%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
$356M49%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
$140M20%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
Income before tax$124M17%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
Income tax$25.5M4%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
$98.1M14%
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001297184-26-000009 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Amphastar Pharmaceuticals, Inc. analysis at Buy Like Buffett